Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 478 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06999694RecruitingPhase 2
Proton radiation with immunotherapy for liver cancer
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06999707RecruitingPhase 2
Radiation plus immunotherapy for advanced liver cancer
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT06999174Recruiting
Using MRI to Study Liver Cancer Treatment
This trial uses special MRI scans to learn more about liver cancer (hepatocellular carcinoma) before and during treatment with TACE or SIRT. It may help doctors better understand how the tumor responds to therapy.
MünsterAges 18 years+ - NCT06999837Recruiting
PSMA PET/CT scan for liver cancer (HCC)
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
ClichyAges 18 years+ - NCT06979219Recruiting
Radioembolization for small liver cancer
This trial tests a treatment called radioembolization for small liver cancers. Radioembolization delivers tiny radioactive beads to the tumor, and the goal is to see if it helps shrink or control the cancer.
GoyangAges 19 years+ - NCT06954467RecruitingPhase 2
Two immunotherapy drugs for advanced liver cancer
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
Hefei, AnhuiAges 18 years+ - NCT06944483Recruiting
Same-Day Radiation Treatment for Large Liver Cancer
This trial tests giving a same-day radiation treatment (radioembolization) for large liver cancers (5 cm or bigger). It might be an option if your liver is still working well and you are in good general health.
GoyangAges 19 years+ - NCT06938945Recruiting
Symptom Tracking App for Liver Cancer Immunotherapy
This trial tests whether using a smartphone app to regularly report your symptoms can help you and your doctor manage side effects better during immunotherapy treatment for liver cancer. It is a study where you would be randomly assigned to either use the app or receive usual care.
Haidian, Beijing MunicipalityAges 18–75 - NCT06929845Recruiting
Organoid models for liver cancer study
This study uses tumor samples to create lab-grown mini-livers (organoids) to better understand liver cancer. It may help researchers learn more about the disease and develop new treatments.
RomaAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Phoenix, ArizonaAges 18 years+ - NCT06904170RecruitingPhase 2/Phase 3
Immunotherapy with or without liver artery chemo for liver cancer
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
BordeauxAges 18 years+ - NCT06902389RecruitingPhase 1/Phase 2
Multi-target immune cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy (multi-target Hi-TCR-T cells) for people with advanced liver cancer that hasn't responded to earlier treatments. The therapy targets several markers on your cancer cells to try to attack the tumor more effectively.
Shanghai, Yangpu DistrictAges 18–75 - NCT06893887Recruiting
Personalized treatment for advanced liver cancer
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
Nanjing, JiangsuAges 18 years+ - NCT06880523RecruitingPhase 2
Adding lenvatinib to immunotherapy for liver cancer
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Calgary, AlbertaAges 18 years+ - NCT06882876Enrolling by invitationPhase 1
Study of JS014, Toripalimab and TACE for Untreated Liver Cancer
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
Changsha, HunanAges 18–75 - NCT06885879Recruiting
Studying ctDNA changes after radiation for liver cancer
This trial studies how radiation therapy (SBRT) affects a DNA fragment in the blood called ctDNA in people with liver cancer. By tracking ctDNA changes, doctors hope to better understand how well the treatment is working and possibly predict outcomes earlier.
Hong KongAges 18 years+ - NCT06860490RecruitingPhase 2
Liver cancer trial: HAIC plus immunotherapy and anti-angiogenesis
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT06828380RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
GoyangAges 19 years+
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 478 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.